Criteria for the use of monoclonal antibodies, legislation and ethical considerations.
The criteria governing the in vivo use of monoclonal antibodies in humans are based upon a number of legal requirements with respect to radiation hygiene, pharmaceutical legislation, radiopharmaceutical legislation and regulations with respect to products arising from biotechnology. This in itself has led to a complicated situation which has undoubtedly restricted the development of valuable diagnostic and potential therapeutic agents. From the ethical point of view there are also important considerations, firstly with respect to the methods of producing antibodies, which has resulted in the discontinuation of the raising of antibodies in murine ascites, and secondly in consideration of the ethics of administering labelled antibodies to healthy volunteers and to patients who may not necessarily benefit personally from the procedure. These factors must be evaluated in the light of the EEC document 'Good clinical practice for trials in medicinal products in the European Community from the CPMP working party on Efficacy of Medicinal Products'.
Department of Nuclear Medicine, Dr Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands.
P H
PH
Cox
D000818:Animals; D000911:Antibodies, Monoclonal; D004992:Ethics, Medical; D032984:Ethics, Research; D005062:European Union; D064368:Healthy Volunteers; D006805:Human Experimentation / Q000331:legislation & jurisprudence; D006801:Humans; D051379:Mice; D009683:Nuclear Medicine / Q000331:legislation & jurisprudence*
D000911:Antibodies, Monoclonal